Literature DB >> 15123331

Neurochemical diagnosis of Alzheimer's dementia by CSF Abeta42, Abeta42/Abeta40 ratio and total tau.

Piotr Lewczuk1, Hermann Esselmann, Markus Otto, Juan Manuel Maler, Andreas Wolfram Henkel, Maria Kerstin Henkel, Oliver Eikenberg, Christof Antz, Wolf-Rainer Krause, Udo Reulbach, Johannes Kornhuber, Jens Wiltfang.   

Abstract

Cerebrospinal fluid (CSF) concentrations of amyloid beta peptides ending at positions 42 and 40 (Abeta42 and Abeta40, respectively), and total tau (tTau) protein were measured by ELISA in order to compare their accuracy in discriminating patients with Alzheimer's disease (AD, n = 22), non-Alzheimer dementia (nAD, n = 11) and control subjects (CON, n=35). As compared to the other groups, the concentrations of Abeta42 and tTau were decreased (P<0.001) and increased (P<0.001) in AD, respectively, while Abeta40 did not differ significantly among the groups. Receiver operating characteristic (ROC) analysis was performed to define cut-off values for maximized sensitivity and specificity. For all groups compared the Abeta peptide ratio 42/40 classified more patients correctly, as compared to the concentration of Abeta42 alone: AD versus controls, 94 and 86.7%; AD versus nAD, 90 and 85% and AD versus nAD plus controls, 90.8 and 87%, respectively. The percentage of correctly classified patients was further improved when the Abeta ratio was combined with the analysis of the tTau concentration. Presence of the apolipoprotein E 4 allele, age or degree of mental disability did not significantly influence the parameters studied.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15123331     DOI: 10.1016/S0197-4580(03)00086-1

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN: 0197-4580            Impact factor:   4.673


  91 in total

1.  Cerebrospinal fluid levels of Aβ42 relationship with cholinergic cortical activity in Alzheimer's disease patients.

Authors:  Alessandro Martorana; Zaira Esposito; Francesco Di Lorenzo; Viola Giacobbe; Giulia Maria Sancesario; Giulia Bucchi; Sonia Bonnì; Sergio Bernardini; Roberto Sorge; Giuseppe Sancesario; Giorgio Bernardi; Carlo Caltagirone; Giacomo Koch
Journal:  J Neural Transm (Vienna)       Date:  2012-03-09       Impact factor: 3.575

Review 2.  Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives.

Authors:  Harald Hampel; Richard Frank; Karl Broich; Stefan J Teipel; Russell G Katz; John Hardy; Karl Herholz; Arun L W Bokde; Frank Jessen; Yvonne C Hoessler; Wendy R Sanhai; Henrik Zetterberg; Janet Woodcock; Kaj Blennow
Journal:  Nat Rev Drug Discov       Date:  2010-07       Impact factor: 84.694

Review 3.  Mechanisms of neural and behavioral dysfunction in Alzheimer's disease.

Authors:  Daniel W Wesson; Ralph A Nixon; Efrat Levy; Donald A Wilson
Journal:  Mol Neurobiol       Date:  2011-03-22       Impact factor: 5.590

4.  Histologically confirmed amyloid deposition and low CSF Abeta42 in a cognitively normal subject.

Authors:  Julius Popp; Dietmar R Thal; Piotr Lewczuk; Jens Wiltfang; Frank Jessen
Journal:  J Neurol       Date:  2007-03-14       Impact factor: 4.849

5.  Prediction and longitudinal study of CSF biomarkers in mild cognitive impairment.

Authors:  Miroslaw Brys; Elizabeth Pirraglia; Kenneth Rich; Sindre Rolstad; Lisa Mosconi; Remigiusz Switalski; Lidia Glodzik-Sobanska; Susan De Santi; Ray Zinkowski; Pankaj Mehta; Domenico Pratico; Leslie A Saint Louis; Anders Wallin; Kaj Blennow; Mony J de Leon
Journal:  Neurobiol Aging       Date:  2007-09-24       Impact factor: 4.673

6.  Tau as a biomarker of neurodegenerative diseases.

Authors:  Susanna Schraen-Maschke; Nicolas Sergeant; Claire-Marie Dhaenens; Stéphanie Bombois; Vincent Deramecourt; Marie-Laure Caillet-Boudin; Florence Pasquier; Claude-Alain Maurage; Bernard Sablonnière; Eugeen Vanmechelen; Luc Buée
Journal:  Biomark Med       Date:  2008-08       Impact factor: 2.851

7.  Decreased brain-derived neurotrophic factor depends on amyloid aggregation state in transgenic mouse models of Alzheimer's disease.

Authors:  Shiyong Peng; Diego J Garzon; Monica Marchese; William Klein; Stephen D Ginsberg; Beverly M Francis; Howard T J Mount; Elliott J Mufson; Ahmad Salehi; Margaret Fahnestock
Journal:  J Neurosci       Date:  2009-07-22       Impact factor: 6.167

8.  Elevation in plasma Abeta42 in geriatric depression: a pilot study.

Authors:  Nunzio Pomara; P Murali Doraiswamy; Lisa M Willoughby; Amy E Roth; Benoit H Mulsant; John J Sidtis; Pankaj D Mehta; Charles F Reynolds; Bruce G Pollock
Journal:  Neurochem Res       Date:  2006-04-01       Impact factor: 3.996

9.  Combined CSF tau, p-tau181 and amyloid-beta 38/40/42 for diagnosing Alzheimer's disease.

Authors:  Volker Welge; Oliver Fiege; Piotr Lewczuk; Brit Mollenhauer; Hermann Esselmann; Hans-Wolfgang Klafki; Stefanie Wolf; Claudia Trenkwalder; Markus Otto; Johannes Kornhuber; Jens Wiltfang; Mirko Bibl
Journal:  J Neural Transm (Vienna)       Date:  2009-01-14       Impact factor: 3.575

Review 10.  Neurochemical dementia diagnostics: assays in CSF and blood.

Authors:  Piotr Lewczuk; Joachim Hornegger; Rüdiger Zimmermann; Markus Otto; Jens Wiltfang; Johannes Kornhuber
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2008-11       Impact factor: 5.270

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.